Healthcare provider profile · identity verified

Kashif Sandhu, MD

Family Practice · CHAMBERSBURG, PA · NPI 1174902985

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	613	174
Lisinopril	Lisinopril	430	127
Amlodipine Besylate	Amlodipine Besylate	322	92
Losartan Potassium	Losartan Potassium	271	86
Simvastatin	Simvastatin	254	74
Metformin Hcl	Metformin Hcl	238	65
Metoprolol Succinate	Metoprolol Succinate	232	75
Potassium Chloride	Potassium Chloride	214	64
Tamsulosin Hcl	Tamsulosin Hcl	198	67
Omeprazole	Omeprazole	192	62
Furosemide	Furosemide	190	57
Levothyroxine Sodium	Levothyroxine Sodium	183	46
Gabapentin	Gabapentin	165	48
Hydrochlorothiazide	Hydrochlorothiazide	165	51
Pantoprazole Sodium	Pantoprazole Sodium	130	42
Eliquis	Apixaban	128	39
Metoprolol Tartrate	Metoprolol Tartrate	123	36
Rosuvastatin Calcium	Rosuvastatin Calcium	114	40
Allopurinol	Allopurinol	100	29
Januvia	Sitagliptin Phosphate	99	18
Alprazolam	Alprazolam	98	28
Clopidogrel	Clopidogrel Bisulfate	90	29
Fluticasone Propionate	Fluticasone Propionate	88	34
Sertraline Hcl	Sertraline Hcl	85	24
Citalopram Hbr	Citalopram Hydrobromide	84	29
Montelukast Sodium	Montelukast Sodium	83	25
Albuterol Sulfate Hfa	Albuterol Sulfate	79	33
Metformin Hcl Er	Metformin Hcl	74	20
Famotidine	Famotidine	68	28
Glipizide Er	Glipizide	65	19
Tramadol Hcl	Tramadol Hcl	61	22
Pravastatin Sodium	Pravastatin Sodium	60	20
Prednisone	Prednisone	60	49
Carvedilol	Carvedilol	57	18
Buspirone Hcl	Buspirone Hcl	53	15
Donepezil Hcl	Donepezil Hcl	53	14
Ezetimibe	Ezetimibe	53	14
Alendronate Sodium	Alendronate Sodium	51	15
Topiramate	Topiramate	51	suppressed
Mirtazapine	Mirtazapine	50	16
Escitalopram Oxalate	Escitalopram Oxalate	49	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	13
Duloxetine Hcl	Duloxetine Hcl	46	17
Ramipril	Ramipril	46	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	44	14
Jardiance	Empagliflozin	44	12
Venlafaxine Hcl Er	Venlafaxine Hcl	41	suppressed
Trazodone Hcl	Trazodone Hcl	40	16
Fenofibrate	Fenofibrate Nanocrystallized	39	suppressed
Glimepiride	Glimepiride	39	12
Zolpidem Tartrate	Zolpidem Tartrate	36	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	35	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	33	suppressed
Baclofen	Baclofen	32	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Ropinirole Hcl	Ropinirole Hcl	32	suppressed
Meloxicam	Meloxicam	31	17
Olmesartan Medoxomil	Olmesartan Medoxomil	31	suppressed
Atenolol	Atenolol	30	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Finasteride	Finasteride	27	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Spironolactone	Spironolactone	23	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Cephalexin	Cephalexin	22	18
Glipizide	Glipizide	22	suppressed
Irbesartan	Irbesartan	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	19
Benazepril Hcl	Benazepril Hcl	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Betamethasone Valerate	Betamethasone Valerate	20	18
Fenofibrate	Fenofibrate	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	12
Bumetanide	Bumetanide	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Azithromycin	Azithromycin	13	13
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Valsartan	Valsartan	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Naproxen	Naproxen	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error